{{ (moduleVm.actions && moduleVm.changeStatus) ? moduleVm.status : '' }} Advances in Off-the-Shelf Immunotherapy: Expert Discussion

Activity Steps

Learning Objectives

After completing this continuing education activity you will be able to:

  1. Summarize recent advances in the study of bispecific T-cell engaging antibodies.
  2. Identify the implications of the recent developments for the treatment of patients with cancer or other diseases and for future research.

Learning Outcomes

Healthcare providers will demonstrate knowledge of bispecific T-cell engaging antibody research by achieving a minimum score of 70% on the outcomes-based posttest.
Price: $12.95

Credits:

  • ANCC 1.0 CH
  • DC - BON 1.0 CH
  • FL - BON 1.0 CH
  • GA - BON 1.0 CH

Lippincott Professional Development is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. This activity is also provider approved by the California Board of Registered Nursing, Provider Number CEP 11749. Lippincott Professional Development is also an approved provider of continuing nursing education by the District of Columbia Board of Nursing, Florida Board of Nursing, and Georgia Board of Nursing, #50-1223.







Test Code: OT1021
Published: October 2021
Expires: 9/6/2024
Sources: Oncology Times
Required Passing Score: 8/10 (80%)
Authors: Dibash Kumar DAS, PHD
Topics: Cancer , Immunotherapy